Loading data for SER — first visit, this takes a few seconds.
Serina Therapeutics Inc. (SER)
NYSE American: SER
· Real-Time Price · USD
2.87
+0.22 (8.30%)
At close: Aug 21, 2026, 3:59 PM
2.80
-2.44%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Serina Therapeutics Inc. (SER) Stock Price, Analysis & Data
8.30% (1D)
| Bid | 2.5 |
| Market Cap | 72.9M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.93M |
| n/a | |
| -1.87 | |
| n/a | |
| -2.73 | |
| P/B (ttm) | 3.37 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.82 |
| Volume | 46,000 |
| Avg. Volume (20D) | 84,122 |
| Open | 2.67 |
| Previous Close | 2.65 |
| Day's Range | 2.63 - 2.87 |
| 52-Week Range | 1.22 - 7.92 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 29, 2018
Employees 16
Stock Exchange NYSE American
Ticker Symbol SER
Website https://serinatherapeutics.com
Financial Performance
In 2025, Serina Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -19.18M, an increase of 72.17%.
Financial StatementsEarnings Surprise
Serina Therapeutics has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.52 misses estimates by -0.17, with 21.21% YoY growth.
